BloodSurf 2016: Blood-Biomaterial Interactions

BloodSurf 2016：血液与生物材料的相互作用

基本信息

批准号：
9125521
负责人：
ROBERT A LATOUR
金额：
$ 2万
依托单位：
CLEMSON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-01 至 2017-10-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9125521
关键词：
Address Adverse effects Anticoagulation Antiplatelet Drugs Area Aspirin Award Back Biocompatible Materials Biomaterials Research Blood Blood Platelets Blood Vessels Blood coagulation Cardiovascular Diseases Cardiovascular system Catheters Clinical Coagulation Process Collaborations Communities Comorbidity Complex Development Device or Instrument Development Devices Diabetes Mellitus Disabled Persons Discipline Disease Engineering Event Fostering Funding Goals Hematologist Hematology Hemorrhage Hemostatic function Heparin In Vitro Inflammation Inflammatory International Joints Lead Learning Link Location Mechanics Mediating Medical Device Medical Students Medicine Membrane Proteins Minority Modern Medicine Molecular Oral Patient Monitoring Patients Pharmaceutical Preparations Plavix Postdoctoral Fellow Reaction Research Research Personnel Resistance Schedule Scientist Seasons Stents Structure Students Surface System Testing Therapeutic Thrombosis Thrombus Travel Universities Vascular Diseases Warfarin Whole Blood Woman blood oxygenator clinically significant clopidogrel cost design effective therapy falls improved in vivo interest medical schools meetings professor research study response symposium ventricular assist device

项目摘要

DESCRIPTION (provided by applicant): Biomaterial-induced thrombus formation is the number one clinical problem common to all blood-contacting medical devices that are used in the treatment of cardiovascular and vascular disease, ranging from relatively simple catheters, balloons, and stents to complex mechanical systems such as ventricular assist devices (VADs). While antithrombotic and antiplatelet drugs, such as heparin and clopidogrel (Plavix), are commonly used to suppress biomaterial-induced thrombus formation for patients undergoing treatment with such devices, these types of drugs inhibit blood coagulation systemically, which can lead to other clinically significant bleeding-related complications. More effective treatments for cardiovascular and vascular disease would be provided from the development of thrombus-resistant biomaterials that would eliminate, or at least greatly reduce, the need for the use of systemic antithrombotic therapies. However, a limited understanding of the specific mechanisms underlying thrombotic reactions to synthetic materials following their contact with blood continues to hinder the development of new clinical devices and treatments for cardiovascular and vascular disorders. Addressing this problem requires the efforts of researchers and practitioners from diverse fields-in particular, this requires close interaction between biologists chemists, physicists, and engineers with clinical practitioners. The specific purpose of the BloodSurf 2016 Symposium (September 13-16, 2016, Babson Executive Conference Center, Wellesley, MA) is to bring together experts from these respective disciplines along with students and postdoctoral fellows who share a common interest in the development of thrombo-resistant biomaterials for four days immersed in presentations and discussions about the critical needs and research directions for the development of medical devices with improved blood compatibility. Recognizing the key role of platelets in mediating blood response to biomaterials and the need for closer integration with scientists and clinicians within the general hemostasis and thrombosis community, this symposium will be linked with the 9th Platelets International Symposium that is being coordinated by Dr. Alan D. Michelson, Director for Platelet Research Studies and Professor of Medicine, Harvard Medical School, and Dr. David Varon, Professor of Hematology, Hebrew University of Jerusalem. The Platelets International Symposium will follow BloodSurf 2016, including a one-day set of combined sessions. Because BloodSurf 2016 represents a unique meeting that falls outside of the normally scheduled set of professional conferences held each year, funding support is requested to offset the costs of attendance for our set of 16 invited speakers as well as providing eight student/postdoc travel awards (four of which will be set aside for the support of women, minorities, and persons with disabilities). Narrative: Biomaterial-induced thrombus formation is the number one clinical problem common to all blood-contacting medical devices that are used in the treatment of cardiovascular and vascular disease. The BloodSurf 2016 Symposium will bring together leading scientists, engineers, and clinicians interested in improving the blood compatibility of blood-contacting medical devices for four days of focused presentations and discussions. Funding support is requested to offset travel costs for our set of 16 invited speakers and to provide eight travel awards for students and postdoctoral fellows to attend this symposium.

描述（由申请人提供）：生物材料引起的血栓形成是用于治疗心血管和血管疾病的所有血液接触医疗器械所共有的第一大临床问题，从相对简单的导管、球囊和支架到复杂的机械系统，如心室辅助装置（VAD），而抗血栓和抗血小板药物，如肝素和氯吡格雷（波立维），通常用于抑制生物材料引起的。对于接受此类装置治疗的患者来说，这些类型的药物会全身抑制血液凝固，从而导致其他临床上显着的出血相关并发症，抗血栓生物材料的开发将为心血管和血管疾病提供更有效的治疗。然而，对合成材料与血液接触后发生血栓反应的具体机制的了解仍然有限，这仍然阻碍了新的临床设备和药物的开发。心血管治疗解决这个问题需要来自不同领域的研究人员和从业者的努力——特别是，这需要生物学家、化学家、物理学家和工程师与临床从业者之间的密切互动。BloodSurf 2016 研讨会（9 月 13 日至 16 日）的具体目的。，2016 年，巴布森行政会议中心，韦尔斯利，马萨诸塞州）将汇集来自这些学科的专家以及对发展有共同兴趣的学生和博士后研究员抗血栓生物材料为期四天，沉浸在有关开发具有改善血液相容性的医疗器械的关键需求和研究方向的演讲和讨论中，认识到血小板在介导血液对生物材料的反应中的关键作用以及与血小板更紧密结合的必要性。广大止血和血栓形成领域的科学家和人群，本次研讨会将与由血小板研究主任 Alan D. Michelson 博士协调的第九届血小板国际研讨会联系在一起哈佛医学院医学研究教授和耶路撒冷希伯来大学血液学教授 David Varon 博士将在 BloodSurf 2016 之后举办血小板国际研讨会，其中包括为期一天的联合会议，因为 BloodSurf 2016 代表了一次独特的会议。会议不属于每年举行的正常安排的专业会议范围，需要资金支持来抵消我们 16 名受邀演讲者的出席费用，并提供 8 名学生/博士后旅行奖励（其中四项将专门用于支持妇女、少数民族和残疾人）。叙述：生物材料引起的血栓形成是所有用于治疗心血管和血管疾病的血液接触医疗设备所面临的首要临床问题。BloodSurf 2016 研讨会将汇集对改善血栓问题感兴趣的顶尖科学家、工程师和战士。血液接触医疗设备的血液兼容性需要为期四天的集中演示和讨论，以抵消我们 16 名受邀演讲者的旅行费用，并为学生和学生提供八个旅行奖励。博士后参加本次研讨会。